发明名称 |
SINGLE NUCLEOTIDE POLYMORPHISMS USEFUL TO PREDICT CLINICAL RESPONSE FOR GLATIRAMER ACETATE |
摘要 |
<p>This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of 1) identifying whether the human subject is a predicted responder to glatiramer acetate by determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of the SNPs in Group 1; and 2) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.</p> |
申请公布号 |
KR20140101730(A) |
申请公布日期 |
2014.08.20 |
申请号 |
KR20147012550 |
申请日期 |
2012.10.09 |
申请人 |
TEVA PHARMACEUTICAL INDUSTRIES LTD. |
发明人 |
TCHELET AMIR;MACCIARDI FABIO;LEVY JOSEPH |
分类号 |
A61K31/195;A61K48/00;A61P25/00;C12Q1/68 |
主分类号 |
A61K31/195 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|